These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10683491)

  • 1. Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
    Fukuzaki K; Kamenosono T; Nagata R
    Pharmacol Biochem Behav; 2000 Mar; 65(3):503-8. PubMed ID: 10683491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
    Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
    Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
    Kuzel MD
    Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist.
    Parker SG; Raval P; Yeulet S; Eden RJ
    Eur J Pharmacol; 1994 Nov; 265(1-2):17-26. PubMed ID: 7883025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
    Tulloch IF
    Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.
    Korczyn AD; Brunt ER; Larsen JP; Nagy Z; Poewe WH; Ruggieri S
    Neurology; 1999 Jul; 53(2):364-70. PubMed ID: 10430427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalent doses of ropinirole and bromocriptine.
    Jost WH
    Eur J Neurol; 1999 Sep; 6(5):618. PubMed ID: 10866496
    [No Abstract]   [Full Text] [Related]  

  • 15. Ropinirole, a non-ergoline dopamine agonist.
    Jost WH; Angersbach D
    CNS Drug Rev; 2005; 11(3):253-72. PubMed ID: 16389293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
    Tel BC; Zeng BY; Cannizzaro C; Pearce RK; Rose S; Jenner P
    Neuroscience; 2002; 115(4):1047-58. PubMed ID: 12453478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-512, a novel dopamine D
    Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C
    Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
    Prikhojan A; Brannan T; Yahr MD
    J Neural Transm (Vienna); 2000; 107(10):1159-64. PubMed ID: 11129105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
    Muriel MP; Orieux G; Hirsch EC
    Mov Disord; 2002 Nov; 17(6):1174-9. PubMed ID: 12465054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.